We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
- Authors
Frandsen, Thomas L; Abrahamsson, Jonas; Lausen, Birgitte; Vettenranta, Kim; Heyman, Mats; Behrentz, Michael; Castor, Anders; Wehner, Peder S; Frost, Britt-marie; Andersen, Elisabeth W; Schmiegelow, Kjeld
- Abstract
This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2), ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
- Publication
British journal of haematology, 2011, Vol 155, Issue 2, p244
- ISSN
1365-2141
- Publication type
Journal Article
- DOI
10.1111/j.1365-2141.2011.08835.x